Eli Lilly has confirmed its plans to acquire Centessa Pharmaceuticals for $6.3 billion, enhancing its portfolio in the biotechnology sector. This acquisition aligns with Centessa's focus on developing transformative treatments for cognitive and attention-related disorders through its innovative orexin receptor 2 agonist program. Despite a recent downgrade by Wells Fargo, which lowered Centessa's rating but raised its price target to $42, the deal underscores the strong market interest in advanced pharmaceutical solutions.
Loading timeline…